Compare Boeing Co (BA) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs BioNTech SE - ADR — how do they compare? Boeing Co trades at $231.01 (market cap $184.35B), while BioNTech SE - ADR trades at $92.94 (market cap $23.31B). The key difference: Boeing Co is far larger — about 7.9× BioNTech SE - ADR's market cap, and Boeing Co pays a 0.03% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BA | BNTX | |
|---|---|---|
Market Cap | $184.35B | $23.31B |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $119.34 |
52-Week Low | $179.12 | $83.89 |
Enterprise Value | $210.23B | $6.60B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $232.14, down 0.28% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company's fundamentals reflect a recovery, with 2025 revenue at $89.46B and net income of $2.24B, though valuation ratios like P/E of 83.9 remain elevated. News highlights Boeing's strategic sale of subsidiaries to Archer Aviation, aiming to streamline operations.
Outlook is cautiously optimistic with a consensus price target of $280.83, implying 21% upside. Key opportunities include production ramp-up and backlog growth, while risks involve high debt, volatile cash flows, and competitive pressures. Investors should monitor execution on profitability targets and macroeconomic impacts on aerospace demand.
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
